Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
559 Leser
Artikel bewerten:
(2)

Sistema PJSFC: Announcement on the acquisition of Nearmedic Group

DJ Sistema PJSFC: Announcement on the acquisition of Nearmedic Group

Sistema PJSFC (SSA) Sistema PJSFC: Announcement on the acquisition of Nearmedic Group 15-Sep-2021 / 19:30 MSK Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

15 September 2021, Moscow - Sistema PJSFC ("Sistema", the "Corporation" or, together with its subsidiaries and affiliates, the "Group") (LSE: SSA, MOEX: AFKS) announces that JSC New Investment Holding^i ("the Buyer") has acquired Nearmedic International Limited, the 100% shareholder of LLC Nearmedic Plus, LLC Nearmedic Pharma, and several other pharmaceutical, biotech, and healthcare businesses in Russia and Italy ("Nearmedic Group" or "Nearmedic") for 1 rouble ("the Transaction"). Nearmedic Group's net debt as of the closing of the Transaction was RUB 5.9bn. Sistema and the Sberbank group of companies ("Sberbank") have in equal parts provided the Buyer with RUB 1.2bn in equity financing that will go towards the partial repayment of Nearmedic's outstanding debt to Sberbank. Sistema and Sberbank have also entered into option agreements, exercisable within 3.5 years from the date of closing, enabling Sistema to buy and Sberbank to sell to Sistema its equity interest in JSC New Investment Holding, with up to RUB 2.8bn in outstanding receivables due from Nearmedic to be transferred from Sberbank to Sistema immediately upon such sale. "Nearmedic Group has growth potential that can be unlocked through restructuring and improvements in efficiency, areas precisely where Sistema has robust, proven expertise. We also have a strong track record in pharmaceuticals, healthcare and biotech, all of which are key business lines for Nearmedic. We will shortly begin implementing a turnaround plan for Nearmedic Group focused on boosting the value of the company's assets and expanding production capacities," said Sistema President Vladimir Chirakhov. Nearmedic Group consists of pharmaceutical, biotech, and medical assets. The company's core businesses are the design and production of original medications; the development, manufacturing and sale of diagnostic test kits; the supply of suites of equipment for medical laboratories; and the provision of medical and lab services. Nearmedic Group possesses production facilities in the cities of Obninsk and Mosalsk, a factory producing medical products in Italy, and a chain of multi-specialty medical clinics across Moscow, Obninsk, and Ryazan. *** For further information, please visit www.sistema.com or contact:

Public Relations                   Investor Relations 
Sergey Kopytov                    Nikolai Minashin 
Phone: +7 (495) 228 15 32              Phone: +7 (495) 730 66 00 
kopytov@sistema.ru                  n.minashin@sistema.ru 
 some 150 million customers in the sectors of telecommunications, high technology, financial services, retail, paper and packaging, agriculture, real estate, tourism and medical services. The company was founded in 1993. Revenue in 2020 was RUB 691.6 billion; total assets equalled RUB 1.4 trillion as of 31 December 2020. Sistema's global depositary receipts are listed under the "SSA" ticker on the London Stock Exchange. Sistema's ordinary shares are listed under the "AFKS" ticker on the Moscow Exchange. Website: www.sistema.com 

---------------------------------------

(i) JSC New Investment Holding is jointly controlled by the Group and Sberbank, which own 50%+1 shares and 50%-1 shares in its equity, respectively.

-----------------------------------------------------------------------------------------------------------------------

ISIN:     US48122U2042 
Category Code: MSCM 
TIDM:     SSA 
LEI Code:   213800JSZ2UUK4QQK694 
Sequence No.: 122264 
EQS News ID:  1233676 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1233676&application_name=news

(END) Dow Jones Newswires

September 15, 2021 12:30 ET (16:30 GMT)

© 2021 Dow Jones News
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.